CYP2C9 genetic variants and losartan oxidation in a Turkish population

European Journal of Clinical Pharmacology

Volumn 60, Issue 5, 2004, Pages 337-342

  Babaoglu, Melih O ^a   Yasar, Umit ^a   Sandberg, Mia ^b   Eliasson, Erik ^b   Dahl, Marja Liisa ^c   Kayaalp, S Oguz ^a   Bozkurt, Atila ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2C9 polymorphism; Losartan; Phenotyping

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DRUG METABOLITE; LOSARTAN; LOSARTAN POTASSIUM;

ADULT; ARTICLE; DRUG OXIDATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TURKEY (REPUBLIC); URINALYSIS; YEAST;

EID: 4043095409     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0785-5     Document Type: Article

References (31)

1. 450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48:409-415
2. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R (2001) Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharm Ther 70:391-394
3. Caraco Y, Muszkat M, Wood AJ (2001) Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11:587-596
4. 450enzymes. Clin Pharmacol Ther 73:517-528
5. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607
6. Daly AK, King BP (2003) Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13:247-252
7. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387
8. 450 2C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79:841-847
9. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355
10. 450family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90
11. 450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10:85-89
12. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9:71-80
13. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803-808
14. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr (2001) Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 41:715-722
15. 450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-263
16. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Differences in flurbiprofen pharmacokinetics between CYP2C9*1/ *1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 58:791-794
17. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA (2003) Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84-91
18. Schwarz UI (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33[Suppl 2]:23-30
19. 450 2C9 in a Caucasian and a Black-African population. Br J Clin Pharmacol 52:447-450
20. Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R, Kimura K, Iga T (2003) Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 59:589-592
21. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfleld GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349
22. Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 73:253-263
23. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251
24. Wang SL, Huang J, Lai MD, Tsai JJ (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42
25. Yasar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631
26. Yasar Ü, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjöqvist F, Dahl M-L (2001) The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 57:729-735
27. Yasar Ü, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E (2001) Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051-1056
28. Yasar Ü, Aklillu E, Canaparo R, Sandberg M, Sayi J, Roh H-K, Wennerholm A (2002) Analysis of CYP2C9*5 in Caucasian. Oriental and Black-African populations. Eur J Clin Pharmacol 58:555-558
29. Yasar Ü, Dahl M-L, Christensen M, Eliasson E (2002) Intra-individual variability in urinary losartan oxidation ratio, an in vivo-marker of CYP2C9 activity. Br J Clin Pharmacol 54:183-185
30. Yasar Ü, Forslund C, Tybring O, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl M-L (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98
31. Yasar Ü, Lundgren S, Eliasson E, Bennet A, Wiman B, De Faire U, Rane A (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299:25-28